Journal of Pharmacotherapy and Clinical Translational Research (JPCTR) is proud to present the latest issue featuring cutting-edge research and reviews in pharmacotherapy and clinical translational research. Below, you will find the table of contents for the current issue:
Featured Articles in the Latest Issue
- Volume 2 (Issue 2) JULY – DECEMBER 2025
Research Articles
Pharmacogenomic information to Warfarin clinical dosing guidelines: A multi-ethnic validation
Vol.2(2); Pages:1-10. Published on July 2025
Abstract
Population variability and lack of generalizability of algorithms are the barriers to clinical use of pharmacogenomic-guided warfarin dosing. This was a prospective multicenter observational study that sought to determine the accuracy of a multi-ethnic pharmacogenomic dosing algorithm in Malaysia and the Netherlands. A sample population of 420 patients was genotyped CYP2C9, VKORC1 and CYP4F2 alleles followed-up during the initiation of warfarin use. Target International Normalized Ratio (INR) was reached in 78 percent of patients with a mean of 4 days (p < 0.001) as compared to conventional dosing techniques. This evidence backs the clinical relevance of pharmacogenomic-based solutions to manage individual anticoagulation treatment, as they have the potential to increase the accuracy of warfarin dosing, decrease the adverse effects, and maximize the use of this medication in various populations. The study recommends that custom pharmacogenomic interventions should be coupled into regular clinical practice to enhance patient outcomes in the world.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Real-Life Efficacy of SGLT2 Inhibitors in HFpEF: Translational Retrospective Cohort-Study
Vol.2(2); Pages:11-21. Published on July 2025
Abstract
Although the therapy with SGLT2 inhibitors (SGLT2i) in heart failure with preserved ejection fraction (HFpEF) patients has been proven in randomized controlled trials (RCTs), real-world results have not been explored well. This retrospective cohort study tried to estimate the efficacy of empagliflozin and dapagliflozin in HFpEF patients within 12 months in two tertiary centers. The number of patients involved in the analysis was 634. The utilization of SGLT2i was linked to the reduced incidence of HF-related hospitalizations (31.8 percent, p < 0.01) and a tremendous enhancement in New York Heart Association (NYHA) functional category in 45.6 percent of participants. The profile of adverse events was in line with those previously witnessed in clinical trials. The translational study closes the gap between the trial-based evidence and the clinical practice, which justifies the newer role of SGLT2 inhibitors as a component of HFpEF pharmacotherapy.
View Full PDF
Please LOGIN to View Full PDF or Read more.
The Prediction of Clinical Response in Rheumatoid Arthritis IL-6 inhibitors and biomarkers relative evaluation
Vol.2(2); Pages:22-31. Published on August 2025
Abstract
The treatment of rheumatoid arthritis (RA) through interleukin-6 (IL-6) inhibitors is one of the game changers, but each patient responds to treatment rather differently. The purpose of this comparative effectiveness study was to evaluate the clinical effectiveness of tocilizumab and sarilumab and determine whether they are related to the level of inflammatory biomarkers, taking the level of IL-6 and C-reactive protein (CRP) in the blood of 232 patients with RA. By 24 weeks, Disease Activity Score 28- CRP (DAS28-CRP) remission rates were more significant in patients whose IL-6 level had been high at the test start (p = 0.002). On the other hand, those patients with low biomarker expression had an equal efficacy between both drugs. These estimations provide support to the idea of biomarker profiling in the personalization of RA treatment and imply that the level of IL6 might become a predictive indicator helping to choose between tocilizumab and sarilumab. The research recommends the application of biomarkers of inflammation in clinical decision making to achieve the best treatment of rheumatoid arthritis.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Levetiracetam TDM in Practice: a Pharmacokinetic Pharmacodynamic Approach of a Population
Vol.2(2); Pages:32-40. Published on August 2025
Abstract
A well-known anticonvulsant levetiracetam is commonly utilized in epilepsy treatment, but in parallel with a significant person-to-person variation in its therapeutic response, it is important to use personalized dosing approaches. In this research paper, the population pharmacokinetic (PK)/pharmacodynamic (PD) modeling was done to optimize the use of therapeutic drug monitoring (TDM) of levetiracetam in 180 patients with focal and generalized seizures. Plasma levels, the frequency of seizures, and the pattern of side effects were assessed during the 6 months and analyzed. The three variables that the population PK/PD model found were covariates were due to age, renal function, and the CYP2C19 genotype; they affected the clearance of the drug. It is important to note that the frequency of seizures was reduced by 41 per cent more in patients whose treatment with levetiracetam was individualised after model-based TDM than in standard care (p < 0.001). The study justifies the use of PK/PD modeling and therapeutic drug monitoring to achieve an optimal control of epilepsy underlining the advantages of individual treatment in managing epilepsy care.
View Full PDF
Please LOGIN to View Full PDF or Read more.
In Post-COVID Pulmonary Fibrosis: Translational Safety and Efficacy of Repurposed Antiviral Agents
Vol.2(2); Pages:41-49. Published on September 2025
Abstract
Pulmonary fibrosis occurring after COVID-19 (post-COVID pulmonary fibrosis, or PCPF) is a relatively recent problem that receives little treatment, and clinical attention focuses on it. The present pilot open-label clinical trial applied efficacy measurements in evaluating the off-label administration of nintedanib and favipiravir to 34 patients diagnosed with moderate to severe PCPF. The 12-week follow-up of the patients was performed with measures of primary outcomes concentrated on lung functioning (FVC), dependency on oxygen, and fibrosis markers. Nintedanib group of patients demonstrated a substantial 12.7 percent mean improvement in forced vital capacity (FVC) (p = 0.041), whereas favipiravir had little impact on biomarkers even where the disease had not shown improvement. The two agents were quite tolerated with a transient elevation in ALT being reported in 3 patients. This paper suggests the prospective rates of antiviral drug repurposing in the treatment of fibrotic lung disease and its drawbacks in enhancing clinical outcomes. Further testing of the effectiveness of these agents in the management of post-COVID pulmonary fibrosis must be done in larger controlled trials.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Access the full articles by clicking on the titles and provided links.
For full access to all articles and supplementary materials, please visit our journal archive or subscribe to our journal. We encourage readers to explore these contributions and share their insights with the research community.
